What is Juniper Genomics?
Juniper Genomics is redefining the landscape of IVF care through the application of advanced genomic analysis. Unlike conventional screening methods that often rely on polygenic risk scores, Juniper utilizes a comprehensive approach that examines millions of genetic markers to identify conditions associated with IVF failure, miscarriage, and long-term health outcomes. Founded by a multidisciplinary team of experts in genomics, reproductive medicine, and bioethics, the company is establishing a new standard for embryo health assessment. Its market position is characterized by a commitment to both scientific rigor and ethical transparency, addressing a critical need for actionable insights in the fertility sector.
The company's growth trajectory is supported by a robust intellectual foundation, enabling it to navigate the complex regulatory and clinical environments inherent in reproductive technology. By integrating deep sequencing capabilities with a patient-centric model, Juniper Genomics is effectively bridging the gap between laboratory innovation and clinical application.
How much funding has Juniper Genomics raised?
Juniper Genomics has raised a total of $4.6M across 1 funding round:
Seed
$4.6M
Seed (2025): $4.6M with participation from Amboy Street Ventures, MBX Capital, Blue Collective, and Innospark Ventures
Key Investors in Juniper Genomics
Amboy Street Ventures
Amboy Street Ventures is a specialized venture capital fund dedicated to the women's health and sexual wellbeing sector, focusing on Seed and Series A startups that address critical gaps in fertility and maternal health.
MBX Capital
MBX Capital is a boutique firm that partners with early-stage healthcare and biotechnology companies, specifically targeting ventures that disrupt conventions in public health through innovative scientific applications.
Blue Collective
Blue Collective is a values-driven investment firm that employs a multi-strategy model to support exceptional entrepreneurs, emphasizing a people-first approach to building remarkable businesses.
What's next for Juniper Genomics?
With this recent capital injection, Juniper Genomics is well-positioned to accelerate its operational scaling and expand its clinical footprint. The strategic focus will likely center on enhancing its sequencing infrastructure and broadening the accessibility of its screening services to fertility clinics globally. As the company transitions from its initial development phase into a broader commercial rollout, the emphasis will remain on validating its diagnostic accuracy and fostering partnerships within the reproductive health ecosystem. Investors are betting on the company's ability to disrupt the status quo of IVF, potentially setting a new benchmark for how genetic data is utilized to improve reproductive success rates and long-term health outcomes for families.
See full Juniper Genomics company page
